Beta blockers may increase risk of hypoglycemia in individuals using which therapies?

Beta blockers may increase risk of hypoglycemia in individuals using which therapies?

• A. Glucose intolerance
• B. Renal impairment
• C. Hyperlipidemia
• D. Insulin or insulin secretagogues

Answer: (D)

Beta blockers can blunt the body’s warning signs of falling blood glucose and, at the same time, interfere with glucose production when it’s needed. This is especially risky for people using insulin or insulin secretagogues, because these therapies actively lower glucose or boost insulin release. If a beta blocker blocks beta-2 receptors in the liver, glycogenolysis and gluconeogenesis are reduced, so the liver has a harder time raising glucose during hypoglycemia, which can prolong or worsen the low. Additionally, the adrenergic symptoms that usually cue someone to treat low blood sugar—like tremor and rapid heartbeat—may be damped, delaying recognition and treatment. That combination makes the risk of hypoglycemia highest with insulin or insulin secretagogues. Glucose intolerance, renal impairment, and hyperlipidemia don’t have the same direct interaction with beta blockers to raise hypoglycemia risk in this context.

Beta blockers can blunt the body’s warning signs of falling blood glucose and, at the same time, interfere with glucose production when it’s needed. This is especially risky for people using insulin or insulin secretagogues, because these therapies actively lower glucose or boost insulin release. If a beta blocker blocks beta-2 receptors in the liver, glycogenolysis and gluconeogenesis are reduced, so the liver has a harder time raising glucose during hypoglycemia, which can prolong or worsen the low. Additionally, the adrenergic symptoms that usually cue someone to treat low blood sugar—like tremor and rapid heartbeat—may be damped, delaying recognition and treatment. That combination makes the risk of hypoglycemia highest with insulin or insulin secretagogues. Glucose intolerance, renal impairment, and hyperlipidemia don’t have the same direct interaction with beta blockers to raise hypoglycemia risk in this context.